🇺🇸 FDA
Pipeline program

Amifampridine Phosphate

LMS-002

Phase 3 small_molecule completed

Quick answer

Amifampridine Phosphate for Lambert Eaton Myasthenic Syndrome is a Phase 3 program (small_molecule) at CATALYST PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
CATALYST PHARMACEUTICALS, INC.
Indication
Lambert Eaton Myasthenic Syndrome
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials